# Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting

> **NCT03831178** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** Docosahexaenoic acid (DHA)
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03831178
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-28
- **Primary completion:** 2024-12-01
- **Final completion:** 2030-09
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03831178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03831178, "Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03831178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*